Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility

Hvidman, Helene Westring; Bentzen, Jens; Thuesen, Lea Langhoff; Lauritsen, Mette Petri; Forman, Julie Lyng; Loft, Anne; Pinborg, Anja; Andersen, Anders Nyboe

doi:10.1093/humrep/dew032

Cited by 53 publications

(28 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data demonstrate that AMH levels are no different between women with unexplained infertility and healthy community-dwelling women of similar age and BMI. Our findings are consistent with other reports of inability of AMH to discriminate fertility status between various infertility diagnoses compared with fertile controls (47) and within infertility diagnoses (UI vs. male factor) (48).…”

Section: Figuresupporting

confidence: 93%

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility

Greenwood

Cedars

Santoro

et al. 2017

Fertility and Sterility

View full text Add to dashboard Cite

Currently utilized predictors of ovarian reserve do not discriminate women with rigorously defined unexplained infertility from healthy community-based women of similar demographic characteristics. Contrary to our hypothesis, among women with FSH in the normal range (≤12 IU/L), women with unexplained infertility did not show evidence of decreased ovarian reserve as measured by AMH and AFC. Ovarian reserve markers in isolation may not serve as predictors of future fertility.

show abstract

Section: Figuresupporting

confidence: 93%

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility

Greenwood

Cedars

Santoro

et al. 2017

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Somewhat unexpectedly, time to pregnancy is shortest in the quintile of women with the lowest AMH levels, but a part of the reason for this is probably that anovulatory women are included in the study. A recent Danish study including women referred to ART ( n = 382) aged 20–39 years concludes that infertile women do not have diminished AMH level compared with controls with no history of infertility when adjusting for age . However, this study includes anovulatory women too and consequently the infertile group in this study expectedly has higher AMH values.…”

Section: Methodsmentioning

confidence: 88%

The use of anti‐Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and ‐counseling

Pilsgaard

Grynnerup

Løssl

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Ovarian reserve can be determined by serum anti-Müllerian hormone (AMH) level and/or antral follicle count before controlled ovarian stimulation. The aim of controlled ovarian stimulation is to achieve an appropriate number of mature follicles and avoid complications such as ovarian hyperstimulation syndrome. Measurement of the ovarian reserve is useful for clinicians as it predicts the ovarian response to controlled ovarian stimulation. Further, it assists in giving the patient realistic expectations regarding the treatment. By determining the ovarian reserve, the most appropriate stimulation protocol and gonadotropin dose can be chosen specifically for each woman enabling so-called "individualized treatment" in line with the personalized treatment concept. Many benefits come with using AMH as a biomarker for ovarian reserve; the hormone is considered fairly cycle independent apart from a small decrease in the late follicular phase and there is no inter-observer variance. However, the use of AMH also has limitations; since the implementation of AMH in fertility treatment several AMH assays have been developed. This has made direct comparisons of AMH serum levels complicated. Currently, no international standardized assays exist. AMH is a valid predictor of the ovarian response to controlled ovarian stimulation and to some extent the chance of pregnancy in relation to assisted reproductive technology, but AMH is less optimal in prediction of spontaneous pregnancy and live birth after assisted reproductive technology. Accordingly, AMH can be used to optimize gonadotropin stimulation in fertility treatment, but is not recommended as a screening tool in the general population.

show abstract

“…AFC helps to predict whether there is an increased risk of retrieving a small number of oocytes following ovarian stimulation, which results in reduced rate of pregnancy following IVF and lower cumulative pregnancy rate. It is important to note that having a poor ovarian reserve should not be interpreted as being the same as having a reduced chance to conceive spontaneously.…”

Section: Consensusmentioning

confidence: 99%

Counting ovarian antral follicles by ultrasound: a practical guide

Neto

Ludwin

Borrell

et al. 2018

Ultrasound in Obstet & Gyne

108

View full text Add to dashboard Cite

show abstract

Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility

Abstract: Not applicable.

Cited by 53 publications

References 39 publications

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility

The use of anti‐Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and ‐counseling

Counting ovarian antral follicles by ultrasound: a practical guide

Contact Info

Product

Resources

About